Cite
Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)
MLA
Florence Wong, et al. “Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C).” Antiviral Therapy, vol. 24, Jan. 2019, pp. 35–44. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....318774435cd65843366276f38eb1e811&authtype=sso&custid=ns315887.
APA
Florence Wong, Alexander Wong, Fiona McPhee, Misti Linaberry, Stephanie Noviello, Wayne Ghesquiere, Gregory D Huhn, Fred Poordad, Rong Yang, Stephen D. Shafran, Mitchell L. Shiffman, & Alnoor Ramji. (2019). Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C). Antiviral Therapy, 24, 35–44.
Chicago
Florence Wong, Alexander Wong, Fiona McPhee, Misti Linaberry, Stephanie Noviello, Wayne Ghesquiere, Gregory D Huhn, et al. 2019. “Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C).” Antiviral Therapy 24 (January): 35–44. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....318774435cd65843366276f38eb1e811&authtype=sso&custid=ns315887.